OPKO Health Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat OPKO Health de winst en omzet met respectievelijk 49.5% en 6.4% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 46.9% per jaar.

Belangrijke informatie

49.5%

Groei van de winst

46.9%

Groei van de winst per aandeel

Healthcare winstgroei	20.8%
Inkomstengroei	6.4%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	07 Oct 2024

Recente toekomstige groei-updates

Recent updates

Analysts Have Just Cut Their OPKO Health, Inc. (NASDAQ:OPK) Revenue Estimates By 14%

Feb 27

Winst- en omzetgroeiprognoses

NasdaqGS:OPK - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	743	-83	3	N/A	3
12/31/2025	715	-202	-35	N/A	6
12/31/2024	705	-210	-130	N/A	6
6/30/2024	716	-243	-86	-67	N/A
3/31/2024	800	-252	-59	-41	N/A
12/31/2023	863	-189	-44	-28	N/A
9/30/2023	867	-208	-41	-22	N/A
6/30/2023	868	-209	-110	-87	N/A
3/31/2023	913	-291	-120	-98	N/A
12/31/2022	1,004	-328	-120	-95	N/A
9/30/2022	1,220	-317	-94	-69	N/A
6/30/2022	1,426	-202	-28	-4	N/A
3/31/2022	1,559	-117	-36	-8	N/A
12/31/2021	1,775	-30	6	38	N/A
9/30/2021	1,868	76	46	78	N/A
6/30/2021	1,910	71	73	108	N/A
3/31/2021	1,769	121	72	109	N/A
12/31/2020	1,435	31	6	39	N/A
9/30/2020	1,165	-114	-72	-41	N/A
6/30/2020	966	-200	-151	-128	N/A
3/31/2020	891	-293	-182	-167	N/A
12/31/2019	902	-315	-185	-173	N/A
9/30/2019	899	-279	-173	-161	N/A
6/30/2019	920	-244	-181	-159	N/A
3/31/2019	958	-191	-147	-123	N/A
12/31/2018	990	-153	-137	-109	N/A
9/30/2018	929	-295	-112	-72	N/A
6/30/2018	926	-303	-131	-88	N/A
3/31/2018	955	-314	N/A	-94	N/A
12/31/2017	966	-305	N/A	-92	N/A
9/30/2017	1,081	-101	N/A	-64	N/A
6/30/2017	1,133	-80	N/A	-58	N/A
3/31/2017	1,197	-48	N/A	7	N/A
12/31/2016	1,117	-48	N/A	32	N/A
9/30/2016	1,222	-10	N/A	-8	N/A
6/30/2016	1,067	133	N/A	-7	N/A
3/31/2016	753	75	N/A	-84	N/A
12/31/2015	492	-30	N/A	164	N/A
9/30/2015	241	-85	N/A	149	N/A
6/30/2015	118	-262	N/A	159	N/A
3/31/2015	99	-244	N/A	171	N/A
12/31/2014	91	-172	N/A	-90	N/A
9/30/2014	86	-135	N/A	-92	N/A
6/30/2014	87	-147	N/A	-82	N/A
3/31/2014	87	-125	N/A	-64	N/A
12/31/2013	97	-115	N/A	-56	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat OPK de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat OPK de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat OPK de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van OPK ( 6.4% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van OPK ( 6.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van OPK naar verwachting over 3 jaar hoog zal zijn

OPKO Health Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates upgraded to US$0.30 loss, revenue downgraded

Price target decreased by 9.6% to US$3.92

Consensus EPS estimates fall by 16%

Consensus estimates of losses per share improve by 16%

Price target decreased by 11% to US$4.32

Consensus EPS estimates upgraded to US$0.25 loss

Recent updates

OPKO Health, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Not Enough To Keep OPKO Health Flying

Consensus EPS estimates upgraded to US$0.30 loss, revenue downgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

OPKO Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

OPKO Health, Inc. (NasdaqGS:OPK) announces an Equity Buyback for $100 million worth of its shares.

OPKO Health, Inc. announced that it has received $250 million in funding from Healthcare Royalty Management, LLC

Price target decreased by 9.6% to US$3.92

OPKO Health, Inc. announced that it has received $250 million in funding from Healthcare Royalty Management, LLC

Chairman & CEO recently bought US$127k worth of stock

Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

OPKO Health, Inc. announced delayed annual 10-K filing

New major risk - Financial position

Full year 2023 earnings: EPS exceeds analyst expectations

Chairman & CEO recently bought US$992k worth of stock

OPKO Health, Inc. to Report Q4, 2023 Results on Feb 27, 2024

OPKO Health, Inc., Annual General Meeting, Mar 28, 2024

Chairman & CEO recently bought US$1.5m worth of stock

President & Vice Chairman recently bought US$514k worth of stock

New minor risk - Profitability

OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar

Chairman & CEO recently bought US$1.3m worth of stock

Consensus EPS estimates fall by 16%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

OPKO Health, Inc. Presents Late-Breaking Clinical Data on RAYALDEE Extended-Release Calcifediol

OPKO Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is OPKO Health (NASDAQ:OPK) A Risky Investment?

Chairman & CEO recently bought US$176k worth of stock

Chairman & CEO recently bought US$1.2m worth of stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

OPKO Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up

New minor risk - Profitability

Consensus estimates of losses per share improve by 16%

Price target decreased by 11% to US$4.32

Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?

Consensus EPS estimates upgraded to US$0.25 loss

Chief Innovation Officer & Director recently bought US$541k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chairman & CEO recently bought US$264k worth of stock

Chairman & CEO recently bought US$1.2m worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 36%

OPKO Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?

Price target decreased to US$4.95

Chairman & CEO recently bought US$447k worth of stock

Chairman & CEO recently bought US$319k worth of stock

Chairman & CEO recently bought US$319k worth of stock

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

OPKO Health, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chairman & CEO recently bought US$182k worth of stock

Chairman & CEO recently bought US$133k worth of stock

Chairman & CEO recently bought US$413k worth of stock

OPKO Health: Assessing If Significant Potential Can Be Realized

Chairman & CEO recently bought US$214k worth of stock

OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

Chairman & CEO recently bought US$508k worth of stock

OPKO Health, Inc. Announces Leadership Changes for Bioreference Laboratories

Chairman & CEO recently bought US$802k worth of stock

OPKO Health, Inc. Provides Revenue Guidance for the Year 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

OPKO Health, Inc. to Report Q2, 2022 Results on Aug 04, 2022

OPKO Health: 14%+ Short Interest Means More Volatility Over The Near Term

OPKO Health, Inc., Annual General Meeting, Jul 14, 2022

Chairman & CEO recently bought US$1.1m worth of stock

First quarter 2022 earnings: EPS misses analyst expectations

OPKO Health, Inc. (NasdaqGS:OPK) acquired ModeX Therapeutics, Inc. for $300 million.

OPKO Health, Inc. to Report Q1, 2022 Results on May 09, 2022